Vertex Pays $10B for Crinetics and Endocrine Drug

Vertex Pharmaceuticals just dropped $10 billion to acquire Crinetics Pharmaceuticals, locking in a drug aimed at a rare endocrine disorder. This move signals a serious play in specialized medicine, focusing on conditions that might not be household names but represent significant unmet needs.